Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Our volunteers generously give us their time, skills and experience to tell people about our work, and to help us raise vital funds for research into better treatments and ultimately a cure for T1D.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Professor Colin Dayan presented with the 2023 JDRF Rumbough Award
The JDRF David Rumbough Award acknowledges an individual who has made outstanding contributions in the field of type 1 diabetes that have significantly accelerated our mission.
For over 20 years, Professor Dayan has been a leader in type 1 immunotherapy research, and his work has been central to our research strategy and overall mission. He is leading efforts to bring teplizumab, the first disease-modifying therapy approved by the US Food and Drug Administration to Europe and the UK, which would expand treatment options.
He is a leading member of the JDRF-funded UK Type 1 Diabetes Research Consortium, through which he has brought the research community together to accelerate critical research, leverage collective resources, and collaborate to improve type 1 clinical trial delivery.
Currently, Professor Dayan serves as chair of Clinical Diabetes and Metabolism and head of section at Cardiff University School of Medicine and as part-time senior clinical researcher in the Nuffield Department of Medicine at the University of Oxford.
JDRF Chief Scientific Officer Sanjoy Dutta, Ph.D says: “Professor Dayan has played a significant role in advancing disease-modifying therapies for type 1 diabetes that will continue to have a profound impact on the global type 1 research community and those who are affected by the condition. JDRF is proud to honour Professor Dayan for his indelible contributions and work that supports and furthers our mission.”
Donate to JDRF today so that we can continue funding amazing research to develop cures and treatments for type 1 diabetes.
Researchers funded by Breakthrough T1D in America have used small, electrical implant systems in lab-grown, insulin-producing cells.
New research suggests that B cells play a major role in damaging protective immune cells called Tregs. Protecting Tregs could help protect insulin-producing cells in the early stages of T1D.
A major UK study has shown that screening children for type 1 diabetes (T1D) can identify the condition in its earliest stages, before symptoms appear, offering families time, choices, and hope.
The European Commission has approved Teizeild, the European brand name for the immunotherapy teplizumab, for use in people with stage 2 type 1 diabetes (T1D). This marks an important step forward in efforts to delay the progression of the condition.
